UNIVERSITY OF GEORGIA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1785-01-27
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.uga.edu
Clinical Trials
74
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (68 trials with phase data)• Click on a phase to view related trials
Couple-Based Crisis Safety Planning
- Conditions
- Suicidal IdeasSuicidal IdeationCrisis; EmotionalSuicide AttemptsSuicidal ImpulsesSuicidal and Self-injurious Behaviour
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- University of Georgia
- Target Recruit Count
- 100
- Registration Number
- NCT07012824
- Locations
- 🇺🇸
University of Georgia, Athens, Georgia, United States
Renewed Recovery: a Pilot Test of a Web-Based Mindfulness-Based Relapse Prevention Continuing Care Intervention for Alcohol Use Disorder
- Conditions
- Alcohol Use Disorder (AUD)
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- University of Georgia
- Target Recruit Count
- 30
- Registration Number
- NCT06987526
- Locations
- 🇺🇸
Rescue Mission of Middle Georgia, Macon, Georgia, United States
🇺🇸Project Adam, Winder, Georgia, United States
Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Formative Phase)
- Conditions
- HIV Pre-exposure ProphylaxisHEPATITIS C (HCV)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- University of Georgia
- Target Recruit Count
- 45
- Registration Number
- NCT06799702
Carbohydrates and Running Performance
- Conditions
- Nutrition, Healthy
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- University of Georgia
- Target Recruit Count
- 36
- Registration Number
- NCT06742398
- Locations
- 🇺🇸
University of Georgia, Athens, Georgia, United States
Expanding Interventions for Automatically Maintained SIB
- Conditions
- Self-Injurious BehaviorProblem BehaviorIntellectual DisabilityAutism Spectrum DisorderRestricted Behavior
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- University of Georgia
- Target Recruit Count
- 7
- Registration Number
- NCT06739616
- Locations
- 🇺🇸
May Institute, Randolph, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
AN2 Therapeutics Partners with DNDi to Advance Oral Chagas Disease Treatment AN2-502998
AN2 Therapeutics and DNDi announced a collaboration to advance clinical development of AN2-502998, an oral drug candidate with curative potential for chronic Chagas disease affecting 6-7 million people worldwide.
Blue Lake and CyanVac Report Promising Phase 1 Results for Intranasal COVID-19 Vaccine CVXGA
Blue Lake Biotechnology and CyanVac published full Phase 1 data in Science Advances showing their intranasal COVID-19 vaccine candidate CVXGA demonstrated safety and immunogenicity in 72 healthy subjects aged 12-51 years.
Bioxytran's Antiviral PHM23 Selected for University of Georgia's $100M Bird Flu Challenge Submission
Bioxytran's antiviral compound PHM23 has been selected by the University of Georgia for inclusion in their grant submission to the USDA's $100 million Highly Pathogenic Avian Influenza Poultry Innovation Grand Challenge.
2024 RSV Vaccination Guidelines Strengthen Recommendations for Adults 75 and Older
Updated 2024 RSV vaccination guidelines now strongly recommend vaccination for adults 75 and older, while those 60-74 with risk factors should receive the shot, replacing previous shared decision-making approach.
Blue Lake Biotechnology's Nasal COVID-19 Vaccine Shows 86% Efficacy in Phase 1 Trial
Blue Lake Biotechnology's experimental nasal COVID-19 vaccine demonstrated 86% efficacy in reducing symptomatic infections for three months in Phase 1 trials, significantly outperforming existing mRNA boosters.